A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
NCT ID: NCT01860066
Last Updated: 2013-11-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE3
INTERVENTIONAL
2013-12-31
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
QVA149
QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
QVA149
QVA149 via inhaler twice a day
fluticasone/salmeterol
Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
fluticasone/salmeterol
fluticasone/salmeterol via inhaler twice a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QVA149
QVA149 via inhaler twice a day
fluticasone/salmeterol
fluticasone/salmeterol via inhaler twice a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Other protocol-defined inclusion/exclusion criteria may apply.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Mendoza, Mendoza Province, Argentina
Novartis Investigative Site
Mendoza, Mendoza Province, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Tucumán Province, Argentina
Novartis Investigative Site
Antwerp, , Belgium
Novartis Investigative Site
Brussels, , Belgium
Novartis Investigative Site
Genk, , Belgium
Novartis Investigative Site
Gilly, , Belgium
Novartis Investigative Site
Hasselt, , Belgium
Novartis Investigative Site
Jambes, , Belgium
Novartis Investigative Site
Barranquilla, , Colombia
Novartis Investigative Site
Florida Blanca, , Colombia
Novartis Investigative Site
Medellín, , Colombia
Novartis Investigative Site
Cvikov, Czech Republic, Czechia
Novartis Investigative Site
Jindřichův Hradec, Czech Republic, Czechia
Novartis Investigative Site
Karlovy Vary, Czech Republic, Czechia
Novartis Investigative Site
Kuřim, Czech Republic, Czechia
Novartis Investigative Site
Pardubice, Czech Republic, Czechia
Novartis Investigative Site
Teplice, Czech Republic, Czechia
Novartis Investigative Site
Kyjov, CZE, Czechia
Novartis Investigative Site
Guntur, Andhra Pradesh, India
Novartis Investigative Site
Ahmedabad, Gujarat, India
Novartis Investigative Site
Faridabad, Haryana, India
Novartis Investigative Site
Karamsad, India, India
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Nagpur, Maharashtra, India
Novartis Investigative Site
Pune, Maharashtra, India
Novartis Investigative Site
Jaipur, Rajasthan, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CQVA149A2328
Identifier Type: -
Identifier Source: org_study_id